SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q/A-1
{X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1996
Commission File No. 0-19131
MEDIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware 52-1555759
(State or other jurisdiction of (I. R. S. Employer
incorporation or organization) Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301)417-0770
Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the Registrant was required to
file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
As of June 30, 1996, 21,655,284 shares of Common Stock, par value
$0.01 per share, were outstanding.
PART II
OTHER INFORMATION
Item 1. Legal Proceedings - None
Item 2. Changes in Securities - None
Item 3. Defaults upon Senior Securities - None
Item 4. Submission of Matters to a Vote of Security Holders -
[Change in number of authorized shares]
Item 5. Other Information - None
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits:
10.57 Plasma Supply Agreement dated effective as
of February 8, 1996, by and between DCI Management
Group, Inc. and MedImmune, Inc.
10.58 License and Research Support Agreement dated
as of April 16, 1996, between The Rockefeller
University and MedImmune, Inc.
27 Financial Data Schedule
(b) Reports on Form 8-K:
Report Date Event reported
4/18/96 MedImmune and Rockefeller University
Establish Collaboration to Discover
and Commercialize Products for
Prevention and Treatment of
Streptococcus Pneumoniae
4/25/96 MedImmune Reports Product Sales
Increase 116% for Q1 1996
6/6/96 MedImmune Secured Broad Patent
Coverage for Human B19 Parvovirus
Vaccine
6/20/96 MedImmune Announces Proposed Private
Offering of Convertible Debt
MedImmune Reports Data on New Lyme
Disease Vaccine Candidate at
International Lyme Meeting -
Antibodies to Newly Discovered Decorin
Binding Protein Prevent Infection in
Animals
6/20/96 MedImmune In-Licenses Key Human
Papillomavirus Vaccine Intellectual
Property from German Cancer Research
Center
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
MEDIMMUNE, INC.
(Registrant)
Date: October 3, 1996 /s/David M. Mott
President and
Chief Operating Officer
(Principal accounting and
financial officer)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM MEDIMMUNE,
INC.'S QUARTERLY REPORT ON FORM 10-Q FOR THE SIX MONTHS ENDED JUNE 30, 1996
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FILING.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> JUN-30-1996
<CASH> 9,743
<SECURITIES> 71,324
<RECEIVABLES> 7,573
<ALLOWANCES> 0
<INVENTORY> 6,173
<CURRENT-ASSETS> 95,698
<PP&E> 10,445
<DEPRECIATION> 0
<TOTAL-ASSETS> 106,295
<CURRENT-LIABILITIES> 9,750
<BONDS> 0
0
0
<COMMON> 216
<OTHER-SE> 93,478
<TOTAL-LIABILITY-AND-EQUITY> 106,295
<SALES> 13,454
<TOTAL-REVENUES> 18,361
<CGS> 8,122
<TOTAL-COSTS> 28,923
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 120
<INCOME-PRETAX> (8,608)
<INCOME-TAX> 0
<INCOME-CONTINUING> (8,608)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (8,608)
<EPS-PRIMARY> (0.42)
<EPS-DILUTED> (0.42)
</TABLE>
